



Feb 27, 2019

MRI and Biomarkers in Prostate Cancer (Multi-IMPROD)

 [PLOS Medicine](#)


DOI

dx.doi.org/10.17504/protocols.io.ynifvceIvan Jambor¹

¹Janne Verho, Otto Ettala, Juha Knaapila, Pekka Taimen, Kari T. Syvänen, Aida Kiviniemi, Esa Kähkönen, Ileana Montoya Perez, Marjo Seppänen, Antti Rannikko, Outi Oksanen, Jarno Riikonen, Sanna Mari Vimpeli Tommi Kauko, Harri Merisaari, Markku Kallajoki, Tuomas Mirtti, Tarja Lamminen, Jani Saunavaara, Hannu J. Aronen, Peter J. Boström



Ivan Jambor



Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

[Create free account](#)OPEN  ACCESSDOI: <https://dx.doi.org/10.17504/protocols.io.ynifvce>External link: <http://petiv.utu.fi/multiimprod/>

Protocol Citation: Ivan Jambor 2019. MRI and Biomarkers in Prostate Cancer (Multi-IMPROD). **protocols.io** <https://dx.doi.org/10.17504/protocols.io.ynifvce>

Manuscript citation:

Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ, Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine 16(6). doi: [10.1371/journal.pmed.1002813](https://doi.org/10.1371/journal.pmed.1002813)

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Recruitment Status : Completed

Created: February 27, 2019

Last Modified: February 27, 2019







Protocol Integer ID: 20906

Keywords: IMPROD biparametric MRI, diffusion weighted imaging, prostate cancer, PSA, multi-institutional trial, prostate cancer screening, biomarkers in prostate cancer, improd clinical trial, institutional validation trial of improd trial, elevated prostate, improd trial, reporting system as improd trial, targeted biopsy, biomarker, same clinical trial, mri acquisition, biparametric magnetic resonance imaging, weighted imaging acquisition, mri, magnetic resonance imaging, first biopsy, imaging acquisition, institutional validation trial

Abstract

MULTI-IMPROD clinical trial (**ClinicalTrials.gov Identifier NCT02241122**) is a mutli-institutional validation trial of IMPROD trial (**NCT01864135**) using the same clinical trial set up, MRI acquisition and reporting system as IMPROD trial. Multi-IMPROD validated at 4 centers the use of high quality rapid 3 Tesla biparametric magnetic resonance imaging (bpMRI), T2-weighted imaging and three separate diffusion-weighted imaging acquisitions, combined with targeted biopsy (TB) for improving risk stratification of men with elevated prostate-specific antigen (PSA) before their first biopsy.

Attachments

					
Multi_IMPROD_Aera_v2..	Multi-IMPROD_researc...	Manual_for_Multi_IMP...	Manual_for_imaging_I...	IMPROD_MRI_reporting..	IMPROD.pdf
120KB	249KB	56KB	65KB	86KB	57KB

Troubleshooting

